Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL), marking Tempus' first study collaboration with a non-profit foundation.
This multi-year study will enroll FL patients to generate a comprehensive, multi-omic dataset using advanced technologies and techniques, including next generation sequencing, proteomics, and methylation analysis, to facilitate novel research related to precision medicine and biomarker discovery in FL. This study will also contribute critical insights to inform the development and validation of comprehensive whole genome sequencing approaches.
FL is the second most common type of non-Hodgkin lymphoma, accounting for approximately 10-20% of all cases in the U.S1. Despite advances in treatment, about 20% of patients with FL have progressive disease within two years of initial chemoimmunotherapy and a five-year overall survival of 50%2. This study builds on Tempus and IFLI's existing collaboration to create a consolidated, real-world FL data library. By integrating real-world clinical data with advanced molecular profiling, Tempus and IFLI aim to help accelerate the discovery of new insights, support the development of innovative therapies, and enhance outcomes for FL patients worldwide.
"This collaboration with IFLI signifies our shared commitment to generating rich, multimodal datasets that can help transform research for this specific patient population," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "This comprehensive approach will provide researchers with a uniquely deep and actionable understanding of follicular lymphoma, paving the way for new discoveries and personalized treatment strategies."
"At IFLI, we are dedicated to uniting partners in a shared mission to accelerate breakthroughs in follicular lymphoma care and research, and we are grateful for the collaboration from our network that brought this vision to life. Tempus was selected for its unmatched capabilities in molecular profiling and data science, and we're confident they are uniquely positioned to deliver on our shared vision," stated David McCullagh, Managing Director of IFLI. "Together, we aim to create a transformative dataset that integrates real-world clinical insights with advanced testing and analytics to uncover the biological drivers of FL and enable more personalized therapies that improve patient outcomes globally."
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
About the Institute for Follicular Lymphoma Innovation
The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of FL, and to understand the biology of FL. The foundation deploys its budget across grants, project-based partnerships, and venture philanthropic investments to achieve its innovation goals. IFLI promotes collaboration and works to enable data sharing and the exchange of knowledge and expertise among researchers and institutions advancing FL research and for more information on IFLI, visit www.i-fli.org.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of the collaboration with IFLI and of the study. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission ("SEC") as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
1Armitage JO and Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. J Clin Oncol. 1998;16(8):2780–2795.
2Casulo C, Byrtek M, Dawson, KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516–2522. https://doi.org/10.1200/JCO.2014.59.7534
View source version on businesswire.com: https://www.businesswire.com/news/home/20251114839914/en/
Erin Carron
[email protected]